Keros Therapeutics vs Stoke Therapeutics
KROS and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and STOK compare
Stoke Therapeutics is the larger company, worth 8.4 times as much as Keros Therapeutics ($1.7B against $204M).
Keros Therapeutics grew revenue faster over the last twelve months (−83.4% versus −86.2% for Stoke Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −754% at Stoke Therapeutics.
Keros Therapeutics scores higher on the StockData Score (9 against 6 for Stoke Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | STOK |
|---|---|---|
| Size and price | ||
| Market cap | $204M | $1.7B |
| Share price | $10.30 | $26.68 |
| Change, 1 year | −41.0% | 6.2% |
| Change, 5 years | −82.8% | −4.0% |
| Beta (5Y) | 1.11 | 1.62 |
| Employees | 78 | 170 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.1× (better) | 62.4× |
| P/B | 0.7× (better) | 5.0× |
| FCF yield | −23.6% | −10.5% (better) |
| Fair value | $24.09 | $9.57 |
| Margin of safety | 57.3% (better) | −179% |
| Growth | ||
| Revenue growth (TTM) | −83.4% (better) | −86.2% |
| Net income growth (TTM) | −196% (better) | −496% |
| EPS growth (TTM) | −282% (better) | −501% |
| Profitability | ||
| Operating margin | −181% (better) | −810% |
| Net margin | −153% (better) | −754% |
| FCF margin | −119% (better) | −655% |
| Return on equity | −12.6% (better) | −61.1% |
| Return on invested capital | −389% | −252% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −4856.0× |
| Current ratio | 18.14 (better) | 7.69 |
| Altman Z-score | 2.37 | 18.22 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 120% |
| Held by insiders | 53.3% | 41.6% |
| Insider net buying, 12 months | −$447K (better) | −$6.7M |
| Short interest, % of float | 11.7% | 28.5% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- STOK stock overview
- STOK income statement
- STOK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.